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Abstract
Cervical cancer is a serious public-health problem in Asian countries. Since human papilloma-
virus (HPV) infection is the main risk factor for cervical cancer, HPV vaccination is considered a
promising strategy to prevent cervical cancer. However, comprehensive immunogenicity and
safety information for Asian populations is lacking. We searched four electronic databases
including PubMed, EMBASE, Cochrane Library, and clinicaltrials.gov. We reviewed selected
manuscripts and extracted the pooled relative risk (RR) from immunogenicity and safety infor-
mation on HPV vaccination among women in Asian countries. We identified two quadrivalent-
vaccine studies and eight bivalent-vaccine studies conducted in Asian countries. Analysis across
these studies suggested that the HPV vaccines significantly enhanced HPV16- and HPV18-
specific antibody among both uninfected (RR 85.69; 95% confidence interval (CI) 31.51–233.04
and 62.77; 95% CI 37.4–105.51) and infected individuals (RR 8.60; 95% CI 6.95–10.64 and RR 8.13;
95% CI 5.96–11.11). Furthermore, HPV vaccination among Asian populations has a favorable
safety profile, with only slightly higher risks of local (RR: 1.89; 95% CI 1.65–2.17) and systemic
(RR: 1.33; 95% CI 1.18–1.50) adverse events in vaccinated individuals compared with controls.
For Asian populations, HPV vaccines enhance the level of HPV16- and HPV18-specific antibodies
for both uninfected and infected individuals. Also, the risk of adverse events related to vaccin-
ation are acceptable. More data are needed to establish vaccine efficacy with regard to preven-
tion of HPV infection and further outcomes including cervical intraepithelial neoplasia (CIN) and
cervical cancer.
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Introduction
Cervical cancer has become a substantial social and economic issue
in Asian countries. Indeed, more than half of the worldwide inci-
dence and mortality due to cervical cancer in 2012 occurred in this
region (1,2). The number of cases varies widely among Asian coun-
tries, with India and China as leading countries. Moreover, it has
been shown that, during the last two decades, cervical cancer patients
in developing countries have had a lower survival rate compared with
those in developed countries (1,3).
The fact that human papillomavirus (HPV) infection, acquired by
sexual intercourse, is the main risk factor for cervical cancer has been
known since the 1980s (4,5). There are over 100 types of HPV, of
which the high-risk types, particularly HPV16, -18, -31, -52 and -58,
represent the viruses with oncogenic potential (6–8). Part of the strat-
egies aimed at control of cervical cancer is based on prevention of HPV
infection (7). One clinically proven prevention strategy involves HPV
vaccination of young girls before they become sexually active (7,9).
In 2006, a quadrivalent vaccine (for HPV types 6, 11, 16 and 18) and a
bivalent vaccine (for HPV types 16 and 18) were introduced and
licensed in over 100 countries worldwide (10–12). In 2013, HPV vac-
cination was incorporated in the national vaccination programs of
almost 40 countries, especially western and developed countries (9).
To support the implementation of prophylactic HPV vaccin-
ation, clinical trials have been conducted (13–16). The trials have
clearly shown that the HPV vaccines induce high levels of antiviral
antibodies (17–21), prevent infection with HPV types contained in
the vaccine (13,15), and mitigate the development of premalignant
cervical intraepithelial neoplasia (CIN) and cervical cancer (13,16).
HPV vaccines are considered safe, with most of the trials showing
that the adverse events in the vaccinated groups equal those in com-
parator groups (17,18).
Notably, the main clinical trials on HPV vaccination have been
conducted in the western or developed countries (13,14,16,22) and
so far only few Asian countries have participated in HPV vaccin-
ation trials. Therefore, specific information on HPV vaccine
immunogenicity and safety profiles in Asian populations is scarcely
available. Extrapolation of results of vaccine trials from western to
Asian countries is questionable since trials outcome, for example
vaccine efficacy, might be different as it possibly caused by several
variables, including race as well as social and behavioral factors
(23,24). Therefore, it is important to obtain specific estimations of
the characteristics of HPV vaccination in Asian populations, espe-
cially with respect to immunogenicity, efficacy and safety. In this
study, we investigate the immunogenicity and safety profiles of HPV
vaccines among both uninfected and infected populations in Asian
countries by systematically reviewing available scientific evidence
and performing a meta-analysis of randomized controlled trials.
Methods
Databases and search methods
We systematically searched for randomized controlled clinical trials
(RCT) on HPV vaccination among women in Asian countries from
four electronic databases (PubMed, EMBASE, Cochrane Library
and clinicaltrials.gov). We focused on studies that evaluated the
immunogenicity and safety profiles of the vaccination.
On PubMed, we combined the MeSH term and text word from
each of the following keywords: ‘Human Papillomavirus’ (hpv OR
human papillomavirus OR hpv 16 OR hpv 18) AND ‘HPV vaccine’
(papillomavirus vaccine OR vaccine) AND ‘Asia’. We also used the
same keywords in EMBASE using exp (explosion search), ab
(abstract), and ti (article title) commands. Moreover, we searched
‘hpv vaccine’ in the Cochrane Library to detect all clinical trials on
HPV vaccines and screened the studies manually. In addition, we
applied the search term ‘hpv’ in clinicaltrials.gov. Only studies con-
ducted in Asia were included.
Data collection and analysis
We included all RCTs performed in Asian populations that provided
immunogenicity and safety data of HPV vaccination as outcomes.
We only included studies providing the required information for
each outcome. Databases as off 21 November 2014 were used, and
we only included papers written in English. Two reviewers (D.S.
and J.L.) assessed the studies independently and any disagreement
was discussed and solved with a third reviewer (MJP). Based on the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (25), we extracted the following data:
authors, year published, country, protocol number, funding source,
subject gender and age, active component of the vaccine, vaccine
adjuvant, component of the comparator, total sample on both inter-
vention and comparator groups, administration schedule, frequency
of immunogenicity test, immunogenicity assessment method, the
cut-off point for HPV type 16 and 18 analysis, length of the trial,
and the method used for analysis.
The risk of biases from all studies was assessed based on The
Cochrane Collaboration’s tool for assessing risk of bias in randomized
trials (26). We used the categorization ‘low’, ‘high’, and ‘unclear’ risk
of bias to assess this aspect. Irrespective of bias risk, all screened and
selected eligible studies were included in the review and meta-analysis.
To perform the meta-analysis, we extracted immunogenicity
(seroconversion) and safety (local and systemic adverse events) data
from all selected papers. Seroconversion was mainly estimated from
participants who were shown to be seronegative to HPV at the ini-
tial phase of the studies. In addition, we also included study popula-
tions with seropositive results at the beginning of the study to
investigate the influence of HPV vaccination for infected individuals.
Local adverse events included pain, redness and swelling at the site
of injection, while systemic adverse events comprise arthralgia,
fatigue, fever, gastrointestinal symptoms, headache and myalgia.
Relative risks (RR) were calculated from the number of events
including seroconversion and adverse events in vaccinated groups com-
pared with control groups using a random-effects models to obtain the
vaccine immunogenicity and safety profile (27). In order to dealt with
heterogeneity introduced by the differences in the methods and sample
characteristics, we performed a heterogeneity test by quantifying the I2
score based on Cochrane Q test results (28). This method presents a
quantitative value of heterogeneity ranging from 0% to 100% and
according to Cochrane recommendation, I2 of 50% or higher are con-
sidered to have a substantial heterogeneity (29) and sensitivity analysis
was performed. The uncertainty of each result is presented in terms of
95% confidence intervals (CI). In addition, to analyze the impact of
variables on the outcome, we performed subgroup analyses on
immunogenicity profiles based on immunoassay and vaccine type.
Meta-analysis was performed using RevMan 5.3 for Windows.
Results
Article selection process
We identified 465, 454, 84 and 82 articles from PubMed, EMBASE,
Cochrane Library and Clinicaltrial.gov, respectively. From these,
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21 duplicated articles were removed and 1064 articles were screened
based on title and abstract. Most of these articles did not meet the
inclusion criteria. Finally, 19 full-text articles were assessed for eligi-
bility, from which nine articles were excluded for reasons elaborated
in Fig. 1. Finally, 10 articles were considered (30–39) in the system-
atic review and meta-analysis.
Study characteristics
Included studies are listed in Table 1. Clinical trials on HPV vaccin-
ation in Asia were performed in six different countries (Korea, Japan,
India, China, Bangladesh and Malaysia) and funded by three different
companies: Merck, GlaxoSmithKline (GSK), and Grameenphone (the
first two in pharmaceuticals, the latter in telecommunication). Most
of the studies (N = 7) provided their clinical trial registration numbers
(31–35,38,39). In addition, almost all studies (N = 9) included only
women (30–36,38,39). In general, the age of participants in the stud-
ies varied considerably from 9 to 45 years.
Both HPV vaccines were investigated in the 10 different trials: the
bivalent vaccine from GSK (containing HPV types 16 and 18) in eight
trials (31–36,38,39) and the quadrivalent vaccine from Merck (con-
taining HPV types 6, 11, 16 and 18) in two trials (30,37). The major-
ity of the studies included placebo as the comparator (30,33–39); two
studies on the bivalent vaccine used the Hepatitis A virus vaccine
as comparator (31,32). The number of persons included in most of
the studies was less than 1000, but one study in China included 6051
persons, and investigated not only immunogenicity and safety of the
vaccine but also vaccine efficacy on the prevention of 6-months per-
sistence of infection and CIN associated with HPV16 and/or HPV18
infection (39).
Studies with the bivalent vaccine implemented administration
schedules of 0, 1 and 6 months in the trial (31–36,38,39), while
studies with the quadrivalent vaccine implemented an administra-
tion schedule of 0, 2 and 6 (30,37). Although almost all studies per-
formed immunogenicity testing at 7 months in the trial, there was
one study that performed more extensive immunogenicity testing at
7, 12, 14, 36 and 48 months, with the primary endpoint of the latter
study being assessment of vaccine efficacy with respect to prevention
of 6-months persistent infection and/or histopatologically confirmed
CIN associated with HPV16 and/or HPV18 (39).
Specific cut-off points were implemented to determine the status
of HPV-specific antibodies. In the bivalent-vaccine studies, the cut-
off points were 8 EU/mL and 7 EU/mL for antibodies against
HPV16 and -18, respectively (31–35,38,39). The studies involving
the quadrivalent vaccine applied competitive immunoassay, using
20mMU/mL (milli-Merck unit/milliLiter) and 24mMU/mL as cut-
off points for antibodies against HPV16 and HPV18, respectively
(30,37). One study in Bangladesh involving the bivalent vaccine
used ELISA and calculated the cut-off point based on the mean
optical density of 450 nm to determine the presence of HPV-specific
antibodies (36). The study periods in the studies ranged from 7 to
31 months. All studies were performed according to the total vacci-
nated cohort (intention-to-treat) method or per-protocol analysis for
immunogenicity and safety, respectively.
The risk of bias assessment
Although all studies claimed that exact randomized controlled pro-
cedures were performed, only six studies described how these ran-
dom sequences were generated (32–35,38,39) and only five studies
explained in detail how the allocation process of each participant in
either vaccinated or control group was blinded (33–35,38,39). Most
of the studies (N = 6) did not explain how participants and
researchers were blinded (31,33–36,38) or how the outcome assess-
ment process was blinded (N = 9) (30,31,33–39). One study pre-
sented incomplete outcome results (36) and there were four studies
with a unclear risk of bias on selective reporting (Fig. 2).
Immunogenicity profile
As mentioned, the participants’ HPV16- and HPV18-specific anti-
body profiles were determined using specific cut-off points based on
either ELISA for the bivalent vaccine or competitive immunoassay
Figure 1. Flow diagram for selection of studies included in the study.
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Country Korea Japan Korea India China (Hong
Kong)
Korean Bangladesh China Malaysia China
Protocol number – NCT00316693 NCT00290277 NCT00344032 NCT00306241 NCT00485732 – – NCT00345878 NCT00779766
Funding source Merck & Co
Inc
GSK GSK GSK GSK GSK Grameenphone
Ltd
Merck & Co Inc GSK GSK
Gender Female Female Female Female Female Female Female Female and male Female Female
Patient age 9–23 20–25 10–14 18–35 18–35 15–25 9–13 9–45 18–35 18–25
Intervention & comparator




















VLP amount (μg) 20/40/40/20 20 20 NS 20 20 20 20/40/40/20 20 20
Vaccine adjuvant AAHS AS04 AS04 AS04 AS04 AS04 AS04 AAHS AS04 AS04
Comparator Placebo HAV HAV Placebo Placebo Placebo Placebo Placebo Placebo Placebo
Comparator adjuvant AAHS NS NS Al(OH)3 Al(OH)3 Al(OH)3 Al(OH)3 AAHS Al(OH)3 Al(OH)3
Total sample intervention 117 516 160 176 150 149 50 302 135 3026
Included in safety testing 117 516 126 167 145 140 50 302 131 2987
Included in immunogenicity
testing
108 413 120 153 106 137 49 287 126 396
Total sample comparator 59 519 161 178 150 76 17 298 136 3025
Included in safety testing 59 519 132 170 145 68 17 298 131 2985
Included in immunogenicity
testing




0, 2, 6 0, 1, 6 0, 1, 6 0, 1, 6 0, 1, 6 0, 1, 6 0, 1, 6 0, 2, 6 0, 1, 6 0, 1, 6
Frequency of immunogenicity
testing (month)






ELISA ELISA ELISA ELISA ELISA ELISA Competitive
immunoassay
ELISA ELISA




8/7 EU/mL 8/7 EU/mL 8/7 EU/mL 8/7 EU/mL 8/7 EU/mL 450 nm 20/24 mMU/mL 8/7 EU/mL 8/7 EU/mL
Length of trial (months) 8 7 10 18 16 10 17 7 16 31
Population for analysis
Immunogenicity ATP cohort ATP cohort ATP cohort ATP cohort ATP cohort ATP cohort ATP cohort ATP cohort ATP cohort ATP cohort
Safety TVC TVC TVC TVC TVC TVC TVC TVC TVC TVC
GSK, GlaxoSmithKline; HPV, human papilolomavirus; AAHS, amorphous aluminum hydroxyphosphate sulfate; AS04, aluminum hydroxide and 3-O-desacyl-4’-monophosphoryl lipid A; HAV, Hepatitis A virus;





















for the quadrivalent vaccine. Furthermore, seroconversion was cal-
culated by comparing the patients’ status at the start of the study
(month 0) and 1 month after the last dose (month 7), and pooled
RR of seroconversion among both vaccinated and control groups
was analyzed using a random-effects model. We also describe the
seroconversion according to the type of vaccine (bivalent or quadri-
valent). In addition, there were significant differences on Geometric
Mean Titer (GMT) between vaccinated and comparator groups
with mean differences of 11 866.60 (95% CI 8 443.93–15 289.25)
and 5724.71 (95% CI 3685.09–7764.33) for HPV-16 and HPV-18,
respectively (data not shown).
There was a higher number of seroconversions on HPV16-
specific antibodies in the vaccinated groups compared with the con-
trol groups, and the difference was statistically significant (RR at
62.52; 95% CI 16.29–239.96). However, the heterogeneity among
the pooled studies was moderately high (I2 = 88%; P value < 0.001).
This heterogeneity was remarkably caused by a study from India as
it has a narrow confidence interval and its mean estimate was far
from the ones estimated from the other studies included in the meta-
analysis. A sensitivity analysis, excluding a study from India, showed
that the difference was consistently high (RR at 75.54; 95% CI
30.76–185.46) and the heterogeneity was moderately low (I2 =
47%; P value <0.07) (data not shown). With respect to vaccine type,
the pooled RR on seroconversion for the 7 RCTs using the bivalent
vaccine and 2 RCTs using quadrivalent was 44.86 (95% CI 11.90–
169.15) and 252.65 (95% CI 35.77–1784.59), respectively. The
influence of each individual study on the pooled immunogenicity was
comparable, with equal weights for each study lying between 9%
and 13.6% (Fig. 3).
A positive influence from HPV vaccination with regard to
HPV18-specific immunogenicity (6 RCTs; 2472 participants) was
observed, with a pooled RR of 50.14 (95% CI 31.17–80.68).
Moreover, there was no significant heterogeneity among the studies
(I2 = 0.00%; P value = 0.88). Six trials were included in the analysis
of the bivalent vaccine’s immunogenicity on HPV18, with a pooled
RR at 43.22 (95% CI 25.35–73.68), illustrating a significant increase
in seroconversion due to vaccination. As expected, the quadrivalent
vaccine also demonstrated a statistically significant increase in the
Figure 2. Risk of bias: author’s judgment about each risk of bias item presented as percentages across all included studies.
Figure 3. Comparison of human papillomavirus (HPV) vaccines versus control regarding HPV16-specific antibody conversion rate in HPV-uninfected Asian
populations.
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level of HPV18-specific antibodies (2 RCTs; 737 participants), with a
pooled RR at 96.04 (95% CI 33.87–272.34). The pooled result on
the vaccine’s immunogenicity for HPV18 was strongly influenced by
a single study from Japan with by far the largest number of events
compared with the other studies (Fig. 4).
Furthermore, our pooled analysis showed that HPV vaccines sig-
nificantly stimulated HPV16-specific (RR 8.60; 95% CI 6.95–10.64)
and HPV18-specific (RR at 8.13; 95% CI 5.96–11.11) antibody
levels in combined populations, both infected and uninfected indivi-
duals at the start of the study (Fig. 5). The clinical trial results on the
Figure 4. Comparison of HPV vaccines versus control regarding HPV18-specific antibody conversion rate in HPV-uninfected Asian populations.
Figure 5. Comparison of HPV vaccines versus control regarding HPV16-specific (A) and HPV18-specific (B) antibody conversion rate in combined HPV-infected
and uninfected Asian populations.
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vaccine’s immunogenicity for HPV16 (I2 = 22%; P value = 0.27)
were considerably less heterogenic compared with those for HPV18
(I2 = 65%; P value = 0.01). Again, the study from Japan was of con-
siderable influence.
Safety of the vaccines
Risks of various adverse events, including local and systemic reac-
tions potentially related to the vaccines or the injection procedure,
were calculated from both vaccinated and control groups. Local
adverse events were described as pain, redness and swelling, while
systemic adverse events included arthralgia, fatigue, fever, gastro-
intestinal symptoms, headache and myalgia.
In most studies, local adverse events were reported between 5
and 7 days after each vaccination for both vaccinated and control
groups. The risk of pain after injection in vaccinated groups was
higher than control groups (RR at 1.6; 95% CI 1.36–1.88).
However, the heterogeneity of the results among studies was signifi-
cant (I2: 86.53; P value <0.0001). Among vaccinated individuals,
the risk of swelling at the site of injection was slightly higher (RR at
2.75; 95% CI 2.23–3.38) than the risk of redness (RR at 1.81; 95%
CI 1.53–2.16). Moreover, the heterogeneity of the results on the risk
of swelling among the different studies was low (I2: 34; P value:
0.18). In total, the risk of local adverse events experienced by vacci-
nated groups was higher than control groups (RR at 1.89; 95% CI
1.65–2.17) (Fig. 6).
Systemic adverse events were generally recorded until 30 days
after vaccination. The risks of arthralgia (RR at 1.94; 95% CI
1.55–2.43) and myalgia (RR at 1.84; 95% CI 1.61–2.10) were
higher in the vaccinated groups than in the control groups. Four
types of systemic adverse events had similar risks between vacci-
nated and control groups (fatigue with an RR of 1.17 and 95% CI
of 0.99–1.40, fever with an RR of 1.18 and 95% CI of 0.95–1.48,
GI symptoms with an RR of 1.12 and 95% CI of 0.78–1.62, and
headache with an RR of 1.09 and 95% CI of 0.90–1.31). Finally,
the risk of overall systemic adverse events in the vaccinated groups
was slightly higher than in the controls (RR at 1.33; 95% CI 1.18–
1.50) (Fig. 7).
Figure 6. The risk of local adverse events.
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Figure 7. The risk of systemic adverse events.
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Discussion
Clinical trials, including vaccine-related trials, are often performed in
developed countries such as European countries, the USA, Australia
and Japan (13,14,22,40), since in those countries the infrastructure
and regulations are well established. However, developing countries,
including Asian countries, which are severely affected by infectious
diseases and therefore could benefit substantially from vaccination,
cannot simply adopt the trial results from developed countries, as the
outcomes from vaccination may be different. For example, a study on
rotavirus vaccination showed differences in the performance of the
vaccine, in particular with regard to its protective efficacy, between
developed and developing countries (24). Therefore, evidence from
specific populations, including Asian populations, such as that gener-
ated by the current meta-analysis on HPV vaccination in various
Asian countries, reflects important information for the region.
Currently available prophylactic HPV vaccines offer protection
against cervical cancer and premalignant cervical disease by stimulat-
ing the induction of HPV16- and HPV18-specific antibodies. This
meta-analysis shows that these HPV vaccines are highly immuno-
genic, in terms of induction of HPV16- and HPV18-specific anti-
bodies, in Asian populations. In addition, the aggregate value of the
GMT also demonstrated that HPV vaccines were highly immuno-
genic in terms of HPV-specific antibody stimulation. The current find-
ings on the vaccines’ immunogenicity are perfectly comparable to the
results of numerous studies conducted in western countries, including
the US, European countries, Australia (41–43), or other regions such
as Latin America (40) and Africa (44). The studies evaluated in this
meta-analysis involved similar research methods compared with earl-
ier studies, including sample characteristics, vaccine types, dosing,
and administration schedules. Thus, the similarity in outcomes under-
lines the robustness of the vaccines and indicates that there is little
influence of ethnicity on the performance of the vaccines.
Not only primary HPV infection, but also recurrent infections
may be the cause of the development of HPV-related cancer (45).
This recurrence shows that the antibodies induced by a primary
infection may not always be sufficient to prevent subsequent infec-
tion. Therefore, the application of HPV vaccination of populations
that have already undergone earlier HPV infection and have recov-
ered from this infection, potentially provides benefits by preventing
possible recurrent infection and subsequent cervical cancer in the
future. Our analysis on both infected and uninfected populations
showed that HPV vaccines cause an increase HPV-specific antibody
levels, also in populations that have undergone a prior HPV infec-
tion. Furthermore, our findings are consistent with several studies
on the vaccines’ immunogenicity from other regions in the world,
which also included both uninfected and infected individuals in their
study populations (42–44).
According to our meta-analysis, the safety profiles of HPV vac-
cines were acceptable for Asian populations, with the risk difference
of adverse events for vaccinated and control groups are low. Yet,
some local (injection site related) and systemic reactions (arthralgia
and myalgia) were more common in the vaccinated groups, which is
consistent with previously reported findings from several other
regions (41–44,46). Nevertheless, to obtain a complete description
on HPV vaccines’ safety in Asian populations, further studies should
be performed, including long term effects, adjuvant-based vaccin-
ation and the potential risks of vaccination in pregnancy.
There are several limitations to the evidence presented in this
study. The most important concerns that subgroup analysis on the
participant’s age were not possible since there were only two studies
in young girls’ populations and they did not provide sufficient infor-
mation on immunogenicity and safety of the vaccines. Yet, the study
from Schwarz et al. (18) – enrolling 10–14-year-old girls – and sev-
eral studies concerning older women showed that HPV vaccine
apparently induced high anti-HPV antibody levels up to 6 years
post-vaccination for both age groups. These data underline that
both young girls and older woman may benefit from prophylactic
HPV vaccination, as discussed above.
Heterogeneity in results was observed on the vaccines’ immuno-
genicity for HPV16 in uninfected individuals. According to the sen-
sitivity analysis, this heterogeneity might be caused by differences
related to the trial sites, as most other characteristics of the studies
included in our analysis were comparable and the weight of each
study was equal. Notably, pooled immunogenicity of HPV16 in
uninfected individuals was strongly influenced by one study from
India with the highest numbers of seroconversions in the control
group. Notably, the incidence of HPV infection in India, particularly
that of HPV16, is high compared with other Asian countries
(2,47,48). Exclusion of this study from the analysis resulted in a sub-
stantially lower heterogeneity in the results with respect to immuno-
genicity of the HPV16 component in uninfected individuals.
Publication bias could possibly be caused by the exclusion of
unpublished studies in the meta-analysis (49,50). We used standard
methods to analyze potential publication bias using funnel plots.
With respect to the local and systemic adverse events of HPV vac-
cines, the funnel plots indicated the absence of publication bias
(data not shown). We indeed tried to reduce the risk of publication
bias by including hand search of literature, inspection of the refer-
ence list (snowballing) and searches in databases for ongoing
research. Also, as conflicting results on immunogenicity profiles of
HPV vaccines are rare, we feel that the results of our analysis can be
considered to be valid.
Theoretically, the use of DerSimonian and Laird (DL) generic
random-effects model, which is commonly provided in Meta-
Analysis software, could possibly lead to deficiencies in generating
pooled risk ratio in meta-analyses for relatively low absolute num-
bers of cases, as is the case in our analysis. However, Shuster and
Walker (2014) who reviewed the possible solution for this concern,
found that the majority of meta-analysis studies published in JAMA
provides similar results when it were analyzed with both DL or
Shister, Guo and Skylar (SGS) methods, with the latter being con-
sidered as the possible solution for low-event rates in meta-analysis.
Moreover, the confidence interval generated by these methods were
also considerably similar (51).
Our results provide important information in terms of the
immunogenicity and safety of prophylactic HPV vaccines in Asian
populations. The observation that HPV vaccines are highly
immunogenic and safe for Asian population is consistent with the
outcome of HPV vaccination studies from other regions and under-
lines the robustness of the performance of these vaccines. Since the
correlation between HPV16 or HPV18 infection and the develop-
ment of cervical cancer is well established, implementation of HPV
vaccination as a cervical cancer prevention strategy in Asian coun-
tries seems indicated and justified. Yet, individual country-specific
information, especially cost-effectiveness information (52,53), will
obviously be required for ultimate decision making with regard to
implementation of HPV vaccination in specific Asian countries.
Although promising results on preventing HPV infection, CIN
and cervical cancer were generated by clinical trials on prophylactic
HPV vaccination in several regions in the world (11,54,55), cervical
cancer incidence and mortality in the Asian region remains high, in
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the absence of broad implementation of the vaccines so far (1,2,56).
Only a few countries in Asian regions, including Nepal, and
Malaysia, provide HPV vaccines as national policies (57). This
might be caused by several issues, such as lack of Asian-context-
specific evidence on the efficacy of HPV vaccination, socioeconomic
barriers, and most importantly, scarce national budgets which ham-
per implementation of HPV vaccination in most of Asian countries
(58–60). However, each year of delay means that an entire birth
cohort in a country will miss the opportunity of being offered cer-
vical cancer prevention by HPV vaccination (61). Broader incorpor-
ation of HPV vaccination into national policies could produce
significant benefits with regard to the burden of cervical cancer.
Indeed, factors that contribute to the delay in implementation of
prophylactic HPV vaccination in Asian countries should be
addressed comprehensively.
One important aspect concerns the evidence for efficacy and
safety in the specific Asian context. Notably, as shown here, vaccine
immunogenicity and safety studies from Asian countries show com-
parable outcomes to studies in other regions, including those in
developed countries. For overcoming potential barriers in the area
of socioeconomics, including acceptance, adherence (62,63), educa-
tion and promotion of HPV-related cancer prevention should be fur-
ther substantiated. Direct promotion by health-care professionals is
considered as the optimal strategy (63). In the end, country-specific
information, such as cost-effectiveness studies or budget impact ana-
lysis of HPV vaccination should be performed to ensure allocation
of funding toward optimal preventive strategies against HPV-related
cancer, especially when budgets are limited (64,65).
The results of the present meta-analysis demonstrate that
immunization with the currently available bivalent and quadrivalent
HPV vaccines is immunogenic and safe among Asian populations,
justifying potential incorporation of HPV vaccination in national
cervical-cancer prevention and immunization programs in the
region. Important recent developments in the area of HPV vaccin-
ation include the introduction of a nonavalent vaccine, which covers
more oncogenic HPV types than the current vaccines and potential
dose reductions. A nonavalent HPV vaccine has been approved
recently by the FDA in the US and by the European EMA (8,66).
Introduction of this vaccine will likely result in substantial price
reductions of the current vaccines, which nonetheless prevent the
large majority of cervical cancer cases. This may remove an import-
ant barrier for implementation of HPV vaccination in many Asian
countries. In addition, vaccine dose reductions has been suggested
by several studies from both Asian (67) and other regions (68). This
reduction offers several potential advantages including higher adher-
ence, less budget for it´s implementation and potentially further
decreased risks for any adverse effects. A further important factor in
relation to implementation of HPV vaccination involves the issue of
co-infection with HIV, the latter worsening the prognosis of HPV
infection with enhanced progression to CIN and cervical cancer.
Accelerated implementation of prophylactic HPV vaccination would
appear to be warranted under these conditions.
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